Market Overview

Biogen's Spinraza Could Cost $125,000 Per Dose

Share:
Biogen's Spinraza Could Cost $125,000 Per Dose

According to public pricing database PriceRx, Biogen Inc (NASDAQ: BIIB)'s Spinraza could cost $125,000 per dose. “We had estimated a gross annual price of $450k,” Credit Suisse’s Alethia Young said in a report. She maintains a Neutral rating on the company, with a price target of $312.

Spinraza (nusinersen) is Biogen's drug for spinal muscular atrophy. The company would likely need to pay Ionis Pharmaceuticals Inc (NASDAQ: IONS) a royalty of about 15 percent, analyst Young estimated.

Estimating The Price

The price mentioned by PriceRx would be effective from December 29. This makes the wholesale acquisition cost an estimated ~$750,000 per 12mg dose for the first year and the annual dose in the second year and beyond ~$375,000, with a dose every four months, Young elaborated.

This means that the rough average prices over two and three years are $563,000 and $500,000, respectively. The label indicates that the drug would be given about six times in the first year and three times in the second year.

“We had estimated a gross annual price of $450,000. We had expected the price could be a little higher than our expectations based on other rare disease therapies and truly no options in disease space. We assume in model a 23 percent gross to net and 90 percent compliance. The dose is given via intrathecal injection and so far drug has been well tolerated in clinical trials,” the analyst wrote.

At last check, Biogen shares were down 0.6 percent at $287.50.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2020Morgan StanleyUpgradesUnderweightOverweight
Jul 2020Morgan StanleyMaintainsUnderweight
Jun 2020RBC CapitalMaintainsSector Perform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Alethia YoungAnalyst Color Biotech Health Care Reiteration Analyst Ratings Movers General Best of Benzinga

Latest Ratings

StockFirmActionPT
CAMTNeedhamMaintains18.0
HUBSCitigroupMaintains328.0
SITMNeedhamMaintains67.0
HPCitigroupMaintains19.0
GTESCitigroupMaintains13.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com